Differences in IgG Fc glycosylation are associated with outcome of pediatric meningococcal sepsis

mBio

Volumn 9, Issue 3, 2018, Pages

  de Haan, Noortje ^a   Boeddha, Navin P ^b   Ekinci, Ebru ^b   Reiding, Karli R ^a   Emonts, Marieke ^c,d,e   Hazelzet, Jan A ^f   Wuhrer, Manfred ^a   Driessen, Gertjan J ^b,g  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

^d Infectious Diseases Allergy   (United Kingdom)

^e NEWCASTLE UNIVERSITY   (United Kingdom)

^f ERASMUS MEDICAL CENTER   (Netherlands)

^g JULIANA CHILDREN S HOSPITAL   (Netherlands)

Author keywords

Children; Critical care; Fc glycosylation; Immunoglobulin G; Meningococcal sepsis; N glycan; Outcome

Indexed keywords

ANTIBIOTIC AGENT; GALACTOSE; GLYCAN; GLYCOPEPTIDE; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN G3; INOTROPIC AGENT; PEPTIDE DERIVATIVE; AUTACOID; GLYCOSYLATED IGG; IMMUNOGLOBULIN G;

ADVERSE OUTCOME; ARTICLE; CHILD; CHILD DEATH; CLINICAL OUTCOME; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; FUCOSYLATION; HOSPITAL ADMISSION; HUMAN; HUMAN CELL; INFECTION SENSITIVITY; LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY; MAJOR CLINICAL STUDY; MALE; MENINGOCOCCEMIA; OUTCOME ASSESSMENT; PEDIATRIC INTENSIVE CARE UNIT; PREDICTION; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN GLYCOSYLATION; RETROSPECTIVE STUDY; SCHOOL CHILD; SIALYLATION; BLOOD; GLYCOSYLATION; IMMUNOLOGY; INFANT; MENINGOCOCCOSIS; METABOLISM; NETHERLANDS; PATHOPHYSIOLOGY; SEVERITY OF ILLNESS INDEX;

CHILD; CHILD, PRESCHOOL; FEMALE; GLYCOSYLATION; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; IMMUNOGLOBULIN G; INFANT; INFLAMMATION MEDIATORS; MALE; MENINGOCOCCAL INFECTIONS; NETHERLANDS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX;

EID: 85048803916     PISSN: 21612129     EISSN: 21507511     Source Type: Journal    
DOI: 10.1128/mBio.00546-18     Document Type: Article

References (54)

1. Stoof SP, Rodenburg GD, Knol MJ, Rümke LW, Bovenkerk S, Berbers GA, Spanjaard L, van der Ende A, Sanders EA. 2015. Disease burden of invasive meningococcal disease in the Netherlands between June 1999 and June 2011: a subjective role for serogroup and clonal complex. Clin Infect Dis 61:1281–1292. https://doi.org/10.1093/cid/civ506.
2. ECDC. 2017. Surveillance atlas of infectious diseases. http://atlas.ecdc.europa.eu/public/index.aspx.
3. MacNeil JR, Bennett N, Farley MM, Harrison LH, Lynfield R, Nichols M, Petit S, Reingold A, Schaffner W, Thomas A, Pondo T, Mayer LW, Clark TA, Cohn AC. 2015. Epidemiology of infant meningococcal disease in the United States, 2006–2012. Pediatrics 135:e305–e311. https://doi.org/10.1542/peds.2014-2035.
4. Hadjichristodoulou C, Mpalaouras G, Vasilopoulou V, Katsioulis A, Rachi-otis G, Theodoridou K, Tzanakaki G, Syriopoulou V, Theodoridou M. 2016. A case-control study on the risk factors for meningococcal disease among children in Greece. PLoS One 11:e0158524. https://doi.org/10.1371/journal.pone.0158524.
5. Maat M, Buysse CM, Emonts M, Spanjaard L, Joosten KF, de Groot R, Hazelzet JA. 2007. Improved survival of children with sepsis and purpura: effects of age, gender, and era. Crit Care 11:R112. https://doi.org/10.1186/cc6161.
6. Rivero-Calle I, Vilanova-Trillo L, Pardo-Seco J, Salvado LB, Quinteiro LI, Martinon-Torres F, MENDICOS Research Network. 2016. The burden of pediatric invasive meningococcal disease in Spain (2008–2013). Pediatr Infect Dis J 35:407–413. https://doi.org/10.1097/INF.0000000000001048.
7. Montero-Martín M, Inwald DP, Carrol ED, Martinón-Torres F. 2014. Prognostic markers of meningococcal disease in children: recent advances and future challenges. Expert Rev Anti Infect Ther 12:1357–1369. https://doi.org/10.1586/14787210.2014.966079.
8. Hatherill M, Tibby SM, Turner C, Ratnavel N, Murdoch IA. 2000. Procal-citonin and cytokine levels: relationship to organ failure and mortality in pediatric septic shock. Crit Care Med 28:2591–2594. https://doi.org/10.1097/00003246-200007000-00068.
9. Kornelisse RF, Hazelzet JA, Hop WC, Spanjaard L, Suur MH, van der Voort E, de Groot R. 1997. Meningococcal septic shock in children: clinical and laboratory features, outcome, and development of a prognostic score. Clin Infect Dis 25:640–646. https://doi.org/10.1086/513759.
10. Carrol ED, Thomson AP, Jones AP, Jeffers G, Hart CA. 2005. A predominantly anti-inflammatory cytokine profile is associated with disease severity in meningococcal sepsis. Intensive Care Med 31:1415–1419. https://doi.org/10.1007/s00134-005-2787-x.
11. Pollack MM, Ruttimann UE, Getson PR. 1988. Pediatric risk of mortality (PRISM) score. Crit Care Med 16:1110–1116. https://doi.org/10.1097/00003246-198811000-00006.
12. Couto-Alves A, Wright VJ, Perumal K, Binder A, Carrol ED, Emonts M, de Groot R, Hazelzet J, Kuijpers T, Nadel S, Zenz W, Ramnarayan P, Levin M, Coin L, Inwald DP. 2013. A new scoring system derived from base excess and platelet count at presentation predicts mortality in paediatric meningococcal sepsis. Crit Care 17:R68. https://doi.org/10.1186/cc12609.
13. Pollard AJ, Galassini R, van der Voort EM, Booy R, Langford P, Nadel S, Ison C, Kroll JS, Poolman J, Levin M. 1999. Humoral immune responses to Neisseria meningitidis in children. Infect Immun 67:2441–2451.
14. Vidarsson G, van Der Pol WL, van Den Elsen JM, Vilé H, Jansen M, Duijs J, Morton HC, Boel E, Daha MR, Corthésy B, van De Winkel JG. 2001. Activity of human IgG and IgA subclasses in immune defense against Neisseria meningitidis serogroup B. J Immunol 166:6250–6256. https://doi.org/10.4049/jimmunol.166.10.6250.
15. Aase A, Michaelsen TE. 1994. Opsonophagocytic activity induced by chimeric antibodies of the four human IgG subclasses with or without help from complement. Scand J Immunol 39:581–587. https://doi.org/10.1111/j.1365-3083.1994.tb03416.x.
16. Bredius RG, Derkx BH, Fijen CA, de Wit TP, de Haas M, Weening RS, van de Winkel JG, Out TA. 1994. Fc gamma receptor IIa (CD32) polymorphism in fulminant meningococcal septic shock in children. J Infect Dis 170:848–853. https://doi.org/10.1093/infdis/170.4.848.
17. Caaveiro JM, Kiyoshi M, Tsumoto K. 2015. Structural analysis of Fc/ FcgammaR complexes: a blueprint for antibody design. Immunol Rev 268:201–221. https://doi.org/10.1111/imr.12365.
18. Ferrara C, Grau S, Jäger C, Sondermann P, Brünker P, Waldhauer I, Hennig M, Ruf A, Rufer AC, Stihle M, Umaña P, Benz J. 2011. Unique carbohydrate-carbohydrate interactions are required for high affinity binding between FcgammaRIII and antibodies lacking core fucose. Proc Natl Acad Sci U S A 108:12669–12674. https://doi.org/10.1073/pnas.1108455108.
19. Ercan A, Kohrt WM, Cui J, Deane KD, Pezer M, Yu EW, Hausmann JS, Campbell H, Kaiser UB, Rudd PM, Lauc G, Wilson JF, Finkelstein JS, Nigrovic PA. 2017. Estrogens regulate glycosylation of IgG in women and men. JCI Insight 2:e89703. https://doi.org/10.1172/jci.insight.89703.
20. Pucić M, Knezević A, Vidic J, Adamczyk B, Novokmet M, Polasek O, Gornik O, Supraha-Goreta S, Wormald MR, Redzić I, Campbell H, Wright A, Hastie ND, Wilson JF, Rudan I, Wuhrer M, Rudd PM, Josić D, Lauc G. 2011. High throughput isolation and glycosylation analysis of IgG—variability and heritability of the IgG glycome in three isolated human populations. Mol Cell Proteomics 10:M111.010090. https://doi.org/10.1074/mcp.M111.010090.
21. Wang J, Balog CI, Stavenhagen K, Koeleman CA, Scherer HU, Selman MH, Deelder AM, Huizinga TW, Toes RE, Wuhrer M. 2011. Fc-glycosylation of IgG1 is modulated by B-cell stimuli. Mol Cell Proteomics 10: M110.004655. https://doi.org/10.1074/mcp.M110.004655.
22. Dekkers G, Treffers L, Plomp R, Bentlage AEH, de Boer M, Koeleman CAM, Lissenberg-Thunnissen SN, Visser R, Brouwer M, Mok JY, Mat-lung H, van den Berg TK, van Esch WJE, Kuijpers TW, Wouters D, Rispens T, Wuhrer M, Vidarsson G. 2017. Decoding the human immunoglobulin G-glycan repertoire reveals a spectrum of Fc-receptor-and complement-mediated-effector activities. Front Immunol 8:877. https://doi.org/10.3389/fimmu.2017.00877.
23. Quast I, Keller CW, Maurer MA, Giddens JP, Tackenberg B, Wang LX, Münz C, Nimmerjahn F, Dalakas MC, Lünemann JD. 2015. Sialylation of IgG Fc domain impairs complement-dependent cytotoxicity. J Clin Invest 125:4160–4170. https://doi.org/10.1172/JCI82695.
24. Lu LL, Chung AW, Rosebrock TR, Ghebremichael M, Yu WH, Grace PS, Schoen MK, Tafesse F, Martin C, Leung V, Mahan AE, Sips M, Kumar MP, Tedesco J, Robinson H, Tkachenko E, Draghi M, Freedberg KJ, Streeck H, Suscovich TJ, Lauffenburger DA, Restrepo BI, Day C, Fortune SM, Alter G. 2016. A functional role for antibodies in tuberculosis. Cell 167: 433–443.e14. https://doi.org/10.1016/j.cell.2016.08.072.
25. Ackerman ME, Crispin M, Yu X, Baruah K, Boesch AW, Harvey DJ, Dugast AS, Heizen EL, Ercan A, Choi I, Streeck H, Nigrovic PA, Bailey-Kellogg C, Scanlan C, Alter G. 2013. Natural variation in Fc glycosylation of HIV-specific antibodies impacts antiviral activity. J Clin Invest 123:2183–2192. https://doi.org/10.1172/JCI65708.
26. Kapur R, Della Valle L, Sonneveld M, Hipgrave Ederveen A, Visser R, Ligthart P, de Haas M, Wuhrer M, van der Schoot CE, Vidarsson G. 2014. Low anti-RhD IgG-Fc-fucosylation in pregnancy: a new variable predicting severity in haemolytic disease of the fetus and newborn. Br J Haematol 166:936–945. https://doi.org/10.1111/bjh.12965.
27. Sonneveld ME, Natunen S, Sainio S, Koeleman CA, Holst S, Dekkers G, Koelewijn J, Partanen J, van der Schoot CE, Wuhrer M, Vidarsson G. 2016. Glycosylation pattern of anti-platelet IgG is stable during pregnancy and predicts clinical outcome in alloimmune thrombocytopenia. Br J Haematol 174:310–320. https://doi.org/10.1111/bjh.14053.
28. Parekh RB, Dwek RA, Sutton BJ, Fernandes DL, Leung A, Stanworth D, Rademacher TW, Mizuochi T, Taniguchi T, Matsuta K, et al. 1985. Association of rheumatoid arthritis and primary osteoarthritis with changes in the glycosylation pattern of total serum IgG. Nature 316:452–457. https://doi.org/10.1038/316452a0.
29. Trbojević Akmačić I, Ventham NT, Theodoratou E, Vučković F, Kennedy NA, Krištić J, Nimmo ER, Kalla R, Drummond H, Štambuk J, Dunlop MG, Novokmet M, Aulchenko Y, Gornik O, Campbell H, Pučić Baković M, Satsangi J, Lauc G, IBD BIOM Consortium. 2015. Inflammatory bowel disease associates with proinflammatory potential of the immunoglobulin G glycome. Inflamm Bowel Dis 21:1237–1247. https://doi.org/10.1097/MIB.0000000000000372.
30. Simurina M, de Haan N, Vuckovic F, Kennedy NA, Stambuk J, Falck D, Trbojevic-Akmacic I, Clerc F, Razdorov G, Khon A, Latiano A, D’Inca R, Danese S, Targan S, Landers C, Dubinsky M, IBD BIOM Consortium, McGovern DPB, Annese V, Wuhrer M, Lauc G. 2018. Glycosylation of immunoglobulin G associates with clinical features of inflammatory bowel diseases. Gastroenterology 154:1320–1333.e10. https://doi.org/10.1053/j.gastro.2018.01.002.
31. de Haan N, Reiding KR, Driessen G, van der Burg M, Wuhrer M. 2016. Changes in healthy human IgG Fc-glycosylation after birth and during early childhood. J Proteome Res 15:1853–1861. https://doi.org/10.1021/acs.jproteome.6b00038.
32. Pucic M, Muzinic A, Novokmet M, Skledar M, Pivac N, Lauc G, Gornik O. 2012. Changes in plasma and IgG N-glycome during childhood and adolescence. Glycobiology 22:975–982. https://doi.org/10.1093/glycob/cws062.
33. Sharip A, Sorvillo F, Redelings MD, Mascola L, Wise M, Nguyen DM. 2006. Population-based analysis of meningococcal disease mortality in the United States: 1990–2002. Pediatr Infect Dis J 25:191–194. https://doi.org/10.1097/01.inf.0000202065.03366.0c.
34. Novokmet M, Lukić E, Vučković F, Ðurić Ž, Keser T, Rajšl K, Remondini D, Castellani G, Gašparović H, Gornik O, Lauc G. 2014. Changes in IgG and total plasma protein glycomes in acute systemic inflammation. Sci Rep 4:4347. https://doi.org/10.1038/srep04347.
35. Jones MB, Oswald DM, Joshi S, Whiteheart SW, Orlando R, Cobb BA. 2016. B-cell-independent sialylation of IgG. Proc Natl Acad Sci U S A 113:7207–7212. https://doi.org/10.1073/pnas.1523968113.
36. Manhardt CT, Punch PR, Dougher CWL, Lau JTY. 2017. Extrinsic sialyla-tion is dynamically regulated by systemic triggers in vivo. J Biol Chem 292:13514–13520. https://doi.org/10.1074/jbc.C117.795138.
37. Lee-Sundlov MM, Ashline DJ, Hanneman AJ, Grozovsky R, Reinhold VN, Hoffmeister KM, Lau JT. 2017. Circulating blood and platelets supply glycosyltransferases that enable extrinsic extracellular glycosylation. Glycobiology 27:188–198. https://doi.org/10.1093/glycob/cww108.
38. Shields RL, Lai J, Keck R, O’Connell LY, Hong K, Meng YG, Weikert SH, Presta LG. 2002. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity. J Biol Chem 277:26733–26740. https://doi.org/10.1074/jbc.M202069200.
39. Vestrheim AC, Moen A, Egge-Jacobsen W, Reubsaet L, Halvorsen TG, Bratlie DB, Paulsen BS, Michaelsen TE. 2014. A pilot study showing differences in glycosylation patterns of IgG subclasses induced by pneu-mococcal, meningococcal, and two types of influenza vaccines. Immun Inflamm Dis 2:76–91. https://doi.org/10.1002/iid3.22.
40. Flynn GC, Chen X, Liu YD, Shah B, Zhang Z. 2010. Naturally occurring glycan forms of human immunoglobulins G1 and G2. Mol Immunol 47:2074–2082. https://doi.org/10.1016/j.molimm.2010.04.006.
41. Maier M, Reusch D, Bruggink C, Bulau P, Wuhrer M, Mølhøj M. 2016. Applying mini-bore HPAEC-MS/MS for the characterization and quantification of Fc N-glycans from heterogeneously glycosylated IgGs. J Chromatogr B Analyt Technol Biomed Life Sci 1033–1034:342–352. https://doi.org/10.1016/j.jchromb.2016.08.001.
42. Varki A. 1998. Factors controlling the glycosylation potential of the Golgi apparatus. Trends Cell Biol 8:34–40. https://doi.org/10.1016/S0962-8924(97)01198-7.
43. Plomp R, Ruhaak LR, Uh HW, Reiding KR, Selman M, Houwing-Duistermaat JJ, Slagboom PE, Beekman M, Wuhrer M. 2017. Subclass-specific IgG glycosylation is associated with markers of inflammation and metabolic health. Sci Rep 7:12325. https://doi.org/10.1038/s41598-017-12495-0.
44. Vermont CL, Hazelzet JA, de Kleijn ED, van den Dobbelsteen GP, de Groot R. 2006. CC and CXC chemokine levels in children with meningococcal sepsis accurately predict mortality and disease severity. Crit Care 10:R33. https://doi.org/10.1186/cc4836.
45. de Kleijn ED, de Groot R, Hack CE, Mulder PG, Engl W, Moritz B, Joosten KF, Hazelzet JA. 2003. Activation of protein C following infusion of protein C concentrate in children with severe meningococcal sepsis and purpura fulminans: a randomized, double-blinded, placebo-controlled, dose-finding study. Crit Care Med 31:1839–1847. https://doi.org/10.1097/01.CCM.0000072121.61120.D8.
46. Emonts M, de Bruijne EL, Guimarães AH, Declerck PJ, Leebeek FW, de Maat MP, Rijken DC, Hazelzet JA, Gils A. 2008. Thrombin-activatable fibrinolysis inhibitor is associated with severity and outcome of severe meningococcal infection in children. J Thromb Haemost 6:268–276. https://doi.org/10.1111/j.1538-7836.2007.02841.x.
47. Hermans PW, Hibberd ML, Booy R, Daramola O, Hazelzet JA, de Groot R, Levin M, Meningococcal Research Group. 1999. 4G/5G promoter polymorphism in the plasminogen-activator-inhibitor-1 gene and outcome of meningococcal disease. Lancet 354:556–560. https://doi.org/10.1016/S0140-6736(99)02220-5.
48. Goldstein B, Giroir B, Randolph A, International Consensus Conference on Pediatric Sepsis. 2005. International pediatric sepsis consensus conference: definitions for sepsis and organ dysfunction in pediatrics. Pediatr Crit Care Med 6:2–8. https://doi.org/10.1097/01.PCC.0000149131.72248.E6.
49. Driessen GJ, Dalm VA, van Hagen PM, Grashoff HA, Hartwig NG, van Rossum AM, Warris A, de Vries E, Barendregt BH, Pico I, Posthumus S, van Zelm MC, van Dongen JJ, van der Burg M. 2013. Common variable immunodeficiency and idiopathic primary hypogammaglobulinemia: two different conditions within the same disease spectrum. Haemato-logica 98:1617–1623. https://doi.org/10.3324/haematol.2013.085076.
50. Khemani RG, Bart RD, Alonzo TA, Hatzakis G, Hallam D, Newth CJ. 2009. Disseminated intravascular coagulation score is associated with mortality for children with shock. Intensive Care Med 35:327–333. https://doi.org/10.1007/s00134-008-1280-8.
51. Falck D, Jansen BC, de Haan N, Wuhrer M. 2017. High-throughput analysis of IgG Fc glycopeptides by LC-MS. Methods Mol Biol 1503: 31–47. https://doi.org/10.1007/978-1-4939-6493-2_4.
52. Jansen BC, Falck D, de Haan N, Hipgrave Ederveen AL, Razdorov G, Lauc G, Wuhrer M. 2016. LaCyTools: a targeted liquid chromatography-mass spectrometry data processing package for relative quantitation of glycopeptides. J Proteome Res 15:2198–2210. https://doi.org/10.1021/acs.jproteome.6b00171.
53. Vidarsson G, Dekkers G, Rispens T. 2014. IgG subclasses and allotypes: from structure to effector functions. Front Immunol 5:520. https://doi.org/10.3389/fimmu.2014.00520.
54. Bondt A, Rombouts Y, Selman MH, Hensbergen PJ, Reiding KR, Hazes JM, Dolhain RJ, Wuhrer M. 2014. Immunoglobulin G (IgG) Fab glycosylation analysis using a new mass spectrometric high-throughput profiling method reveals pregnancy-associated changes. Mol Cell Proteomics 13:3029–3039. https://doi.org/10.1074/mcp.M114.039537.